Top Menu

IRF News

NEJM: Call for longer-term studies on ARV toxicity

A recent letter in the NEJM by Janet M. Wojcicki, Ph.D., M.P.H. features the paragraph:

Studies have shown cardiac risks associated with in utero exposure to zidovudine3 and poor growth outcomes at 5 years of age with exposure to nevirapine or zidovudine.4 However, few studies focus on longer-term outcomes in sub-Saharan African populations, and most involve infants in the first few weeks of life or infants younger than 6 weeks of age. This needs to be changed because of the large number of children who will have prolonged exposure to ART in utero and through breast-feeding with Option B+.

, , ,